Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$27.77
+0.4%
$26.77
$23.58
$29.21
$157.65B0.3432.12 million shs28.53 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+0.62%+0.11%-0.82%+12.20%+15.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$27.77
+0.4%
$26.77
$23.58
$29.21
$157.65B0.3432.12 million shs28.53 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+0.62%+0.11%-0.82%+12.20%+15.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.392.23% Upside

Current Analyst Ratings Breakdown

Latest PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetHold$28.00 ➝ $30.00
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$35.00 ➝ $31.00
8/3/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingHold (C)
7/13/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetOutperform$34.00 ➝ $30.00
7/13/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$36.00 ➝ $35.00
7/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetNeutral$27.00 ➝ $26.00
7/8/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetNeutral$30.00 ➝ $28.00
7/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeBuyHold$32.00 ➝ $28.00
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.53$4.41 per share6.29$15.26 per share1.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7636.549.451.866.80%19.63%8.46%11/3/2026 (Estimated)

Latest PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.19%-13.20%226.32%16 Years

Latest PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Huge News For Pfizer Stock Fans
Pfizer Advances PF-07799544 With Completion of Key Phase 1 Study
Pfizer: The 10-Year Is At 5%, And I'm Still Buying This 6%+ Yield
4 stocks to watch on Monday: HPQ, PFE, MRK, and MRVL
Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices
Is Pfizer an Excellent Dividend Stock to Buy?
Is Pfizer an Excellent Dividend Stock to Buy?
Sector Update: Healthcare Stocks Decline Friday Afternoon
Sector Update: Healthcare Stocks Softer Late Afternoon
Pfizer (PFE), What Is Drawing Fresh Attention Now?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pfizer stock logo

Pfizer NYSE:PFE

$27.77 +0.11 (+0.40%)
Closing price 09/21/2026 03:58 PM Eastern
Extended Trading
$27.72 -0.04 (-0.16%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.